Home
News
Create
Screeners
Insights
Brooks Laboratories
96.
28
-6.06
(-5.92%)
Market Cap
₹283.61 Cr
PE Ratio
22.25
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-5.92%
1M
-15.02%
6M
-28.30%
1Y
-32.58%
5Y
+64.75%
View Company Insights
Latest news about Brooks Laboratories
Brooks Laboratories Receives Credit Rating Upgrade, Reflecting Improved Financial Outlook
Nov 12, 2025
CARE Ratings upgraded Brooks Laboratories Limited's (BLL) long-term bank facilities rating to 'CARE BB; Stable' from 'CARE BB-; Stable', while reaffirming its short-term rating at 'CARE A4'. The upgrade is based on expected financial performance improvements and benefits from a merger involving its associate company. BLL projects a total operating income of ~₹100 crore in FY26 with improved profit margins. The merger of BLL's associate, Brooks Steriscience Limited, into OneSource Speciality Pharma Limited is expected to enhance BLL's liquidity and financial risk profile.
Brooks Steriscience Approves Multi-Entity Merger Scheme to Consolidate Sterile Injectable Operations
Sep 26, 2025
Brooks Laboratories Reports Robust Q1 FY26 Results with 265.06 Lakh Net Profit
Aug 13, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation